
The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
To own FIGS, you need to believe it can grow its healthcare professional customer base while protecting margins despite tariffs, competition, and disciplined promotions. The key near term catalyst is whether recent earnings strength can support its higher 2026 revenue guidance, while the biggest current risk remains tariff and sourcing pressure on gross margins. The latest annual meeting and Q1 beat reinforce management stability and execution, but do not materially change that core risk reward balance.
The most relevant update here is FIGS’ first quarter 2026 earnings, which topped analyst expectations on both revenue and earnings and came alongside raised full year revenue growth guidance of 14% to 16%. That financial outperformance gives management more credibility as they speak at conferences and discuss priorities like international expansion and margin recovery, both of which sit at the center of the stock’s current catalyst and risk debate.
Yet investors should still be aware that tariff pressure on key sourcing regions could materially affect...
Read the full narrative on FIGS (it's free!)
FIGS’ narrative projects $862.6 million revenue and $77.4 million earnings by 2029.
Uncover how FIGS' forecasts yield a $17.62 fair value, a 52% upside to its current price.
Some of the most optimistic analysts were already assuming revenue could reach about US$841,200,000 and earnings US$71,200,000 by 2029, so if Q1 strength hints at faster international traction than the base case, you may see that bullish international expansion narrative look less extreme or, if tariffs bite harder, far too hopeful.
Explore 5 other fair value estimates on FIGS - why the stock might be worth as much as 90% more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com